Type I and III interferon production in response to RNA viruses

Journal of Interferon and Cytokine Research

Volumn 34, Issue 9, 2014, Pages 649-658

  Reid, Elizabeth ^a   Charleston, Bryan ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERFERON RECEPTOR;

ANIMAL; BIOSYNTHESIS; DENDRITIC CELL; EPITHELIUM CELL; HUMAN; IMMUNOLOGY; METABOLISM; RNA VIRUS; VIROLOGY; VIRUS REPLICATION;

ANIMALS; DENDRITIC CELLS; EPITHELIAL CELLS; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; RECEPTORS, INTERFERON; RNA VIRUSES; VIRUS REPLICATION;

EID: 84906850729     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0066     Document Type: Review

References (121)

1. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, Paley MA, Antenus M, Williams KL, Erikson J, Wherry EJ, Artis D. 2012. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37(1):158-170.
2. Akira S. 2006. TLR signaling. Current Topics in Microbiology and Immunology 311:1-16.
3. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180(4):2474-2485.
4. Arzt J, Pacheco JM, Smoliga GR, Tucker MT, Bishop E, Pauszek SJ, Hartwig EJ, Santos Tde L, Rodriguez LL. 2014. Foot-andmouth disease virus virulence in cattle is co-determined by viral replication dynamics and route of infection. Virology 452-453:12-22.
5. Baigent SJ, Zhang G, Fray MD, Flick-Smith H, Goodbourn S, McCauley JW. 2002. Inhibition of beta interferon transcription by noncytopathogenic bovine viral diarrhea virus is through an interferon regulatory factor 3-dependent mechanism. J Virol 76(18):8979-8988.
6. Balmelli C, Vincent IE, Rau H, Guzylack-Piriou L, McCullough K, Summerfield A. 2005. Fc gamma RII-dependent sensitisation of natural interferon-producing cells for viral infection and interferon-alpha responses. Eur J Immunol 35(8):2406-2415.
7. Bao X, Liu T, Spetch L, Kolli D, Garofalo RP, Casola A. 2007. Airway epithelial cell response to human metapneumovirus infection. Virology 368(1):91-101.
8. Barber GN. 2001. Host defense, viruses and apoptosis. Cell Death Differ 8(2):113-126.
9. Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, Clarke DL, Message SD, Aniscenko J, Kebadze T, Zhu J, Mallia P, Mizgerd JP, Belvisi M, Papi A, Kotenko SV, Johnston SL, Edwards MR. 2012. Defining critical roles for NF-kappaB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol Med 4(12):1244-1260.
10. Bauhofer O, Summerfield A, Sakoda Y, Tratschin JD, Hofmann MA, Ruggli N. 2007. Classical swine fever virus N-pro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol 81(7):3087-3096.
11. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, Bennett KL, Colinge J, Knapp S, Superti-Furga G. 2010. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 207(12):2689-2701.
12. Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY. 2014. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med 6(3):384-397.
13. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, ter Meulen V, Schneider-Schaulies S. 2002. Hemagglutinin protein of wildtype measles virus activates Toll-like receptor 2 signaling. J Virol 76(17):8729-8736.
14. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE. 2004. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78(24):13779-13792.
15. Broquet AH, Hirata Y, McAllister CS, Kagnoff MF. 2011. RIGI/MDA5/MAVS are required to signal a protective ifn response in rotavirus-infected intestinal epithelium. J Immunol 186(3):1618-1626.
16. Calven J, Yudina Y, Uller L. 2013. Rhinovirus and dsRNA induce RIG-I-like receptors and expression of interferon beta and lambda1 in human bronchial smooth muscle cells. PLoS One 8(4):e62718.
17. Cao W, Liu YJ. 2007. Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol 19(1):24-30.
18. Chakrabarti A, Ghosh PK, Banerjee S, Gaughan C, Silverman RH. 2012. RNase L triggers autophagy in response to viral infections. J Virol 86(20):11311-11321.
19. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA, Dash S. 2014. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol 184(1): 214-229.
20. Charleston B, Brackenbury LS, Carr BV, Fray MD, Hope JC, Howard CJ, Morrison WI. 2002. Alpha/beta and gamma interferons are induced by infection with noncytopathic bovine viral diarrhea virus in vivo. J Virol 76(2):923-927.
21. Charleston B, Hope JC, Carr BV, Howard CJ. 2001. Masking of two in vitro immunological assays for Mycobacterium bovis (BCG) in calves acutely infected with non-cytopathic bovine viral diarrhoea virus. Vet Rec 149(16):481-484.
22. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, Huang J, Renauld JC, Kotenko SV, Roederer M, Beeler JA, Donnelly RP, Collins PL, Rabin RL. 2006. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 80(10):5032-5040.
23. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL. 2006. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12(9):1023-1026.
24. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, Staeheli P, Wack A. 2013. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. Plos Pathog 9(11):e1003773.
25. de Los Santos T, Diaz-San Segundo F, Grubman MJ. 2007. Degradation of nuclear factor kappa B during foot-and-mouth disease virus infection. J Virol 81(23):12803-12815.
26. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282(28):20053-20057.
27. Diaz-San Segundo F, Weiss M, Perez-Martin E, Koster MJ, Zhu J, Grubman MJ, de los Santos T. 2011. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 413(2):283-292.
28. Diebold SS. 2008. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 60(7):813-823.
29. Donnelly RP, Kotenko SV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30(8): 555-564.
30. Dotzauer A, Kraemer L. 2012. Innate and adaptive immune responses against picornaviruses and their counteractions: an overview. World J Virol 1(3):91-107.
31. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896-906.
32. Durbin RK, Kotenko SV, Durbin JE. 2013. Interferon induction and function at the mucosal surface. Immunol Rev 255(1): 25-39.
33. Fensterl V, Sen GC. 2009. Interferons and viral infections. Biofactors 35(1):14-20.
34. Ferreon JC, Ferreon AC, Li K, Lemon SM. 2005. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 280(21):20483-20492.
35. Fiebach AR, Guzylack-Piriou L, Python S, Summerfield A, Ruggli N. 2011. Classical swine fever virus N-pro limits type I interferon induction in plasmacytoid dendritic cells by interacting with interferon regulatory factor 7. J Virol 85(16): 8002-8011.
36. Fitzgerald-Bocarsly P, Feng D. 2007. The role of type I interferon production by dendritic cells in host defense. Biochimie 89(6-7):843-855.
37. Foy E, Li K, Sumpter R, Loo YM, Johnson CL, Wang CF, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 102(8):2986-2991.
38. Francois-Newton V, Almeida GMD, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, Pellegrini S, Uze G. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 6(7):e22200.
39. Garcia-Sastre A. 2011. Induction and evasion of type I interferon responses by influenza viruses. Virus Res 162(1-2):12-18.
40. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401.
41. Glew EJ, Carr BV, Brackenbury LS, Hope JC, Charleston B, Howard CJ. 2003. Differential effects of bovine viral diarrhoea virus on monocytes and dendritic cells. J Gen Virol 84(Pt 7):1771-1780.
42. Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36(2):166-174.
43. Guillerey C, Mouries J, Polo G, Doyen N, Law HKW, Chan S, Kastner P, Leclerc C, Dadaglio G. 2012. Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice. Blood 120(1): 90-99.
44. Guzylack-Piriou L, Bergamin F, Gerber M, McCullough KC, Summerfield A. 2006. Plasmacytoid dendritic cell activation by foot-and-mouth disease virus requires immune complexes. Eur J Immunol 36(7):1674-1683.
45. Heaton NS, Randall G. 2010. Dengue Virus-Induced Autophagy Regulates Lipid Metabolism. Cell Host Microbe 8(5): 422-432.
46. Ho IC. 2009. m(en)TOR(ing) differentiating T helper cells. Immunity 30(6):759-761.
47. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5′-triphosphate RNA is the ligand for RIG-I. Science 314(5801):994-997.
48. Huber JP, Ramos HJ, Gill MA, Farrar JD. 2010. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 185(2):813-817.
49. Ioannidis I, McNally B, Willette M, Peeples ME, Chaussabel D, Durbin JE, Ramilo O, Mejias A, Flano E. 2012. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol 86(10): 5422-5436.
50. Ioannidis I, Ye F, McNally B, Willette M, Flano E. 2013. Tolllike receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 87(6):3261-3270.
51. Iqbal M, Poole E, Goodbourn S, McCauley JW. 2004. Role for bovine viral diarrhea virus Erns glycoprotein in the control of activation of beta interferon by double-stranded RNA. J Virol 78(1):136-145.
52. Isaacs A, Lindenmann J. 1957. Virus Interference. 1. The Interferon. Proc R Soc Ser B Biol Sci 147(927):258-267.
53. Ivashkiv LB, Donlin LT. 2014. Regulation of type I interferon responses. Nat Rev Immunol 14(1):36-49.
54. Iversen MB, Paludan SR. 2010. Mechanisms of type III interferon expression. J Interferon Cytokine Res 30(8):573-578.
55. Jensen S, Thomsen AR. 2012. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol 86(6):2900-2910.
56. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE. 2010. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 84(21):11515-11522.
57. Jilg N, Hatoum IJ, Greenawalt DM, Lin WY, Kaplan LM, Chung RT. 2013. IL28B genotype is not associated with differential gene expression in a large cohort of patients without known HCV infection. Hepatology 58:976a.
58. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Sousa CRE, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089):101-105.
59. Kawashima T, Kosaka A, Yan H, Guo Z, Uchiyama R, Fukui R, Kaneko D, Kumagai Y, You DJ, Carreras J, Uematsu S, Jang MH, Takeuchi O, Kaisho T, Akira S, Miyake K, Tsutsui H, Saito T, Nishimura I, Tsuji NM. 2013. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity 38(6):1187-1197.
60. Kohli A, Zhang X, Yang J, Russell RS, Donnelly RP, Sheikh F, Sherman A, Young H, Imamichi T, Lempicki RA, Masur H, Kottilil S. 2012. Distinct and overlapping genomic profiles and antiviral effects of Interferon-lambda and -alpha on HCV-infected and noninfected hepatoma cells. J Viral Hepat 19(12):843-853.
61. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Uebel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E. 2011. IL-28A (IFN-lambda 2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. Embo Mol Med 3(6):348-361.
62. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
63. Kugel D, Pulverer JE, Koster M, Hauser H, Staeheli P. 2011. Novel nonviral bioassays for mouse type I and type III interferon. J Interferon Cytokine Res 31(4):345-349.
64. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. 2011. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011:349575.
65. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. 2007. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315(5817):1398-1401.
66. Lei X, Xiao X, Xue Q, Jin Q, He B, Wang J. 2013. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. J Virol 87(3):1690-1698.
67. Lester SN, Li K. 2014. Toll-Like Receptors in Antiviral Innate Immunity. J Mol Biol 426(6):1246-1264.
68. Levy DE, Marie IJ, Durbin JE. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1(6):476-486.
69. Li M, Liu X, Zhou Y, Su SB. 2009. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86(1):23-32.
70. Li YZ, Srivastava KK, Platanias LC. 2004. Mechanisms of type I interferon signaling in normal and malignant cells. Arch Immunol Ther Exp 52(3):156-163.
71. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. 2008. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 7(7):1109-1115.
72. Makowska Z, Duong FHT, Trincucci G, Tough DF, Heim MH. 2011. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferonalpha in vivo. Hepatology 53(4):1154-1163.
73. Marshall HD, Urban SL, Welsh RM. 2011. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 85(12):5929-5939.
74. McCullough KC, Ruggli N, Summerfield A. 2009. Dendritic cells-at the front-line of pathogen attack. Vet Immunol Immunopathol 128(1-3):7-15.
75. Megjugorac NJ, Gallagher GE, Gallagher G. 2009. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol 86(6):1359-1363.
76. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. 2012. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56(2):444-454.
77. Newcomer BW, Givens MD. 2013. Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease. Antivir Res 100(1):133-150.
78. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, Himi T, Fujii N, Sawada N. 2011. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res 160(1-2): 360-366.
79. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282(10):7576-7581.
80. Osterlund PI, Pietilae TE, Veckman V, Kotenko SV, Julkunen I. 2007. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 179(6):3434-3442.
81. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. 2012. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56(6):2060-2070.
82. Perez-Martin E, Weiss M, Segundo FDS, Pacheco JM, Arzt J, Grubman MJ, de los Santos T. 2012. Bovine type III interferon significantly delays and reduces the severity of footand-mouth disease in cattle. J Virol 86(8):4477-4487.
83. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reise Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314(5801):997-1001.
84. Pritchard AL, Carroll ML, Burel JG, White OJ, Phipps S, Upham JW. 2012. Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. J Immunol 188(12): 5898-5905.
85. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu LY, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2): 164-171.
86. Randall RE, Goodbourn S. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89(Pt 1):1-47.
87. Rassa JC, Meyers JL, Zhang YM, Kudaravalli R, Ross SR. 2002. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci U S A 99(4):2281-2286.
88. Reid E, Juleff N, Gubbins S, Prentice H, Seago J, Charleston B. 2011. Bovine plasmacytoid dendritic cells are the major source of type I interferon in response to foot-and-mouth disease virus in vitro and in vivo. J Virol 85(9):4297-4308.
89. Richards AL, Jackson WT. 2013. How positive-strand RNA viruses benefit from autophagosome maturation. J Virol 87(18):9966-9972.
90. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. 2009. Activation of innate immune antiviral responses by Nod2. Nat Immunol 10(10): 1073-U49.
91. Schweizer M, Peterhans E. 2001. Noncytopathic bovine viral diarrhea virus inhibits double-stranded RNA-induced apoptosis and interferon synthesis. J Virol 75(10):4692-4698.
92. Seago J, Hilton L, Reid E, Doceul V, Jeyatheesan J, Moganeradj K, McCauley J, Charleston B, Goodbourn S. 2007. The Npro product of classical swine fever virus and bovine viral diarrhea virus uses a conserved mechanism to target interferon regulatory factor-3. J Gen Virol 88(Pt 11):3002-3006.
93. Selvaggi C, Pierangeli A, Fabiani M, Spano L, Nicolai A, Papoff P, Moretti C, Midulla F, Antonelli G, Scagnolari C. 2014. Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. J Infect 68(5): 467-477.
94. Sen A, Pruijssers AJ, Dermody TS, Garcia-Sastre A, Greenberg HB. 2011. The Early Interferon Response to Rotavirus Is Regulated by PKR and Depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol 85(8):3717-3732.
95. Shapira SD, Gat-Viks I, Shum BOV, Dricot A, de Grace MM, Wu LG, Gupta PB, Hao T, Silver SJ, Root DE, Hill DE, Regev A, Hacohen N. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 Infection. Cell 139(7):1255-1267.
96. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. 2014. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15(2):190-202.
97. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68.
98. Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. 2013. IL-28B (IFN-lambda3) and IFN-alpha synergistically inhibit HCV replication. J Viral Hepat 20(4):281-289.
99. Siegel R, Eskdale J, Gallagher G. 2011. Regulation of IFNlambda1 promoter activity (IFN-lambda1/IL-29) in human airway epithelial cells. J Immunol 187(11):5636-5644.
100. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFNlambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e1000017.
101. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, Gale M, Jr., Rosen HR. 2013. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog 9(4):e1003316.
102. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99(24): 15669-15674.
103. Sun JR, Desai MM, Soong L, Ou JHJ. 2011. IFN alpha/beta and autophagy Tug-of-war between HCV and the host. Autophagy 7(11):1394-1396.
104. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. 2009. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci U S A 106(8):2770-2775.
105. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798-801.
106. Thomson SJP, Goh FG, Banks H, Krausgruber T, Kotenko SV, Foxwell BMJ, Udalova IA. 2009. The role of transposable elements in the regulation of IFN-lambda 1 gene expression. Proc Natl Acad Sci U S A 106(28):11564-11569.
107. Tough DF. 2012. Modulation of T-cell function by type I interferon. Immunol Cell Biol 90(5):492-497.
108. Trinchieri G. 2010. Type I interferon: friend or foe? J Exp Med 207(10):2053-2063.
109. Ueki IF, Min-Oo G, Kalinowski A, Ballon-Landa E, Lanier LL, Nadel JA, Koff JL. 2013. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon lambda and antiviral defense in airway epithelium. J Exp Med 210(10): 1929-1936.
110. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52(6):1888-1896.
111. Uze G, Monneron D. 2007. IL-28 and IL-29: newcomers to the interferon family. Biochimie 89(6-7):729-734.
112. van Kasteren PB, Bailey-Elkin BA, James TW, Ninaber DK, Beugeling C, Khajehpour M, Snijder EJ, Mark BL, Kikkert M. 2013. Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells. Proc Natl Acad Sci U S A 110(9):E838-E847.
113. Vilcek J. 2003. Novel interferons. Nat Immunol 4(1):8-9.
114. Wang D, Fang L, Li K, Zhong H, Fan J, Ouyang C, Zhang H, Duan E, Luo R, Zhang Z, Liu X, Chen H, Xiao S. 2012. Footand-mouth disease virus 3C protease cleaves NEMO to impair innate immune signaling. J Virol 86(17):9311-9322.
115. Wang D, Fang L, Li P, Sun L, Fan J, Zhang Q, Luo R, Liu X, Li K, Chen H, Chen Z, Xiao S. 2011a. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J Virol 85(8):3758-3766.
116. Wang D, Fang LR, Zhao FW, Luo R, Chen HC, Xiao SB. 2011b. Molecular cloning, expression and antiviral activity of porcine interleukin-29 (poIL-29). Dev Comp Immunol 35(3): 378-384.
117. Wei H, Wang S, Chen Q, Chen Y, Chi X, Zhang L, Huang S, Gao GF, Chen JL. 2014. Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. PLoS Pathog 10(1):e1003845.
118. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. 2009. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10(8):702-714.
119. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute SB, Garrigues U, Doyle S, Donnelly RP, Kotenko SV, Fitzgerald-Bocarsly P. 2012. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 189(6):2735-2745.
120. Zhang SY, Kodys K, Li K, Szabo G. 2013. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 144(2):414-425.e7.
121. Zhou ZL, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type IIFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mtogen-activated protein kinases. J Virol 81(14): 7749-7758.